 | Up a level |
Novak, Urban; Fehr, Martin; Schär, Sämi; Dreyling, Martin; Schmidt, Christian; Derenzini, Enrico; Zander, Thilo; Hess, Georg; Mey, Ulrich; Ferrero, Simone; Mach, Nicolas; Boccomini, Carola; Böttcher, Sebastian; Voegeli, Michèle; Cairoli, Anne; Ivanova, Vanesa-Sindi; Menter, Thomas; Dirnhofer, Stefan; Scheibe, Bernhard; Gadient, Sandra; ... (2023). Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13). EClinicalMedicine, 64, p. 102221. Elsevier 10.1016/j.eclinm.2023.102221
Heini, Alexander D; Beck, Philipp; Bacher, Ulrike; Seipel, Katja; Zander, Thilo; Daskalakis, Michael; Pabst, Thomas (2023). BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom's Macroglobulinemia. Journal of Clinical Medicine, 12(6) MDPI 10.3390/jcm12062378
Zander, Thilo; Pabst, Thomas; Schär, Sämi; Aebi, Stefan; Mey, Ulrich; Novak, Urban; Lerch, Erika; Rhyner Agocs, Gaëlle; Goede, Jeroen; Maniecka, Zuzanna; Hayoz, Stefanie; Rüfer, Axel; Renner, Christoph; Driessen, Christoph (2023). Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial. Leukemia, 37(3), pp. 699-701. Springer Nature 10.1038/s41375-023-01809-z
Bohler, Jeanne; Bacher, Ulrike; Banz, Yara; Stadelmann, Raphael; Medinger, Michael; Zander, Thilo; Pabst, Thomas (2023). Blinatumomab in Relapsed/Refractory Burkitt Lymphoma. Cancers, 15(1), p. 44. MDPI AG 10.3390/cancers15010044
Farag, Sarah; Bacher, Ulrike; Jeker, Barbara; Legros, Myriam; Rhyner, Gaelle; Lüthi, Jean-Marc; Schardt, Julian; Zander, Thilo; Daskalakis, Michael; Mansouri, Behrouz; Manz, Chantal; Pabst, Thomas (2022). Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial. Bone marrow transplantation, 57(6), pp. 990-997. Springer Nature 10.1038/s41409-022-01681-y
Zander, Thilo; Pabst, Thomas; Schär, Sämi; Aebi, Stefan; Pabst, Tobias; Mey, Ulrich; Novak, Urban; Lerch, Erika; Rhyner, Gaëlle; Goede, Jeroen; Maniecka, Zuzanna; Hayoz, Stefanie; Rufer, Axel; Renner, Christoph; Driessen, Christoph (2021). P-227: Alternate day dosing of pomalidomide in patients with refractory/relapsed multiple myeloma (RRMM): Results of a multicenter, single arm phase 2 trial (SAKK 39/16 OptiPOM Study). Clinical lymphoma, myeloma and leukemia, 21(Suppl. 2), S165-S165. Elsevier 10.1016/S2152-2650(21)02354-5
Prediletto, Irene; Farag, Sarah Ahmed Ibrahim; Bacher, Vera Ulrike; Jeker, Barbara; Mansouri Taleghani, Behrouz; Bregy, Rachel; Zander, Thilo; Betticher, Daniel; Egger, Thomas; Novak, Urban; Pabst Müller, Thomas Niklaus (2019). High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients. Bone marrow transplantation, 54(12), pp. 1923-1925. Nature Publishing Group 10.1038/s41409-019-0508-2
Samaras, Panagiotis; Bargetzi, Mario; Betticher, Daniel C; Driessen, Christoph; Duchosal, Michel A; Heim, Dominik; Ketterer, Nicolas; Lerch, Erika; Matthes, Thomas; Mey, Ulrich; Pabst, Thomas; Schmidt, Adrian; Taverna, Christian; Zander, Thilo; Renner, Christoph (2019). Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss medical weekly, 2019(149), pp. 1-8. EMH Media 10.4414/smw.2019.20031
Amsler, Isabel G; Jeker, Barbara; Mansouri Taleghani, Behrouz; Bacher, Ulrike; Betticher, Daniel; Egger, Thomas; Zander, Thilo; Luethi, Jean-Marc; Novak, Urban; Pabst, Thomas (2019). Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma. Leukemia & lymphoma, 60(2), pp. 511-514. Taylor & Francis 10.1080/10428194.2018.1473577
Zucca, Emanuele; Rondeau, Stephanie; Vanazzi, Anna; Østenstad, Bjørn; Mey, Ulrich J. M.; Rauch, Daniel; Wahlin, Björn E.; Hitz, Felicitas; Hernberg, Micaela; Johansson, Ann-Sofie; de Nully Brown, Peter; Hagberg, Hans; Ferreri, Andrés J. M.; Lohri, Andreas; Novak, Urban; Zander, Thilo; Bersvendsen, Hanne; Bargetzi, Mario; Mingrone, Walter; Krasniqi, Fatime; ... (2019). Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood, 134(4), pp. 353-362. American Society of Hematology 10.1182/blood-2018-10-879643
Driessen, Christoph; Müller, Rouven; Novak, Urban; Cantoni, Nathan; Betticher, Daniel; Mach, Nicolas; Rüfer, Axel; Mey, Ulrich; Samaras, Panagiotis; Ribi, Karin; Besse, Lenka; Besse, Andrej; Berset, Catherine; Rondeau, Stephanie; Hawle, Hanne; Hitz, Felicitas; Pabst Müller, Thomas Niklaus; Zander, Thilo (2018). Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma. Blood, 132(19), pp. 2097-2100. American Society of Hematology 10.1182/blood-2018-05-851170
Gössi, Ursina; Jeker, Barbara; Mansouri Taleghani, Behrouz; Bacher, Vera Ulrike; Novak, Urban; Betticher, Daniel; Egger, Thomas; Zander, Thilo; Pabst, Thomas (2018). Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft. Hematological oncology, 36(2), pp. 436-444. Wiley 10.1002/hon.2490
Bargetzi, Mario; Baumann, Reto; Cogliatti, Sergio; Dietrich, Pierre-Yves; Duchosal, Michel; Goede, Jeroen; Hitz, Felicitas; Konermann, Carolin; Lohri, Andreas; Mey, Ulrich; Novak, Urban; Papachristofilou, Alexandros; Stenner, Frank; Taverna, Christian; Zander, Thilo; Renner, Christoph (2018). Diagnosis and treatment of follicular lymphoma: an update. Swiss medical weekly, 148, w14635. EMH Schweizerischer Ärzteverlag 10.4414/smw.2018.14635
Gautschi, Oliver; Rothschild, Sacha I; Li, Qiyu; Matter-Walstra, Klazien; Zippelius, Alfred; Betticher, Daniel C; Früh, Martin; Stahel, Rolf A; Cathomas, Richard; Rauch, Daniel; Pless, Miklos; Peters, Solange; Froesch, Patrizia; Zander, Thilo; Schneider, Martina; Biaggi, Christine; Mach, Nicolas; Ochsenbein, Adrian (2017). Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clinical lung cancer, 18(3), pp. 303-309. Elsevier 10.1016/j.cllc.2016.11.007
Gilli, Stefanie; Novak, Urban; Mansouri Taleghani, Behrouz; Baerlocher, Gabriela M.; Leibundgut, Kurt; Banz Wälti, Yara; Zander, Thilo; Betticher, Daniel; Egger, Thomas; Rauch, Daniel; Pabst, Thomas (2017). BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients. Annals of hematology, 96(3), pp. 421-429. Springer 10.1007/s00277-016-2900-y
Samaras, Panagiotis; Bargetzi, Mario; Betticher, Daniel C; Duchosal, Michel A; Heim, Dominik; Hess, Urs; Ketterer, Nicolas; Lerch, Erika; Matthes, Thomas; Mey, Ulrich; Pabst, Thomas; Taverna, Christian; Zander, Thilo; Renner, Christoph (2015). Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss medical weekly, 145, w14100. EMH Schweizerischer Ärzteverlag 10.4414/smw.2015.14100
Hofer, Silvia; Elandt, Katarzyna; Greil, Richard; Hottinger, Andreas F; Huber, Urs; Lemke, Dieter; Marosi, Christine; Ochsenbein, Adrian; Pichler, Josef; Roelcke, Ulrich; Weder, Patrik; Zander, Thilo; Wick, Wolfgang; Weller, Michael (2011). Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta oncologica, 50(5), pp. 630-5. Stockholm: Acta Oncologica 10.3109/0284186X.2011.572913
